All In Biotech

Drug Trial Radar · NCT01572727

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.

Last checked: Nov 20, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Aug 2012

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • PaclitaxelDrug

    intravenous paclitaxel 80 mg/m2 per week given until progression

  • BKM120 matching placeboDrug

    Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.

  • BKM120Drug

    Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Assessed by Local Investigator's Assessment (Phase ll)Time frame: Every 8 weeks from randomization until disease progression up to 10 months after futility was analyzed

Locations

112 sites in 22 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers SC

    Chandler, Arizona

  • Arizona Oncology Associates Dept of Oncology

    Phoenix, Arizona

  • Highlands Oncology Group Dept of Highlands Oncology Grp

    Fayetteville, Arkansas

  • California Cancer Care Marian Speciality

    Greenbrae, California

  • Rocky Mountain Cancer Centers RMCC Hale Pkwy

    Greenwood Village, Colorado

  • H. Lee Moffitt Cancer Center & Research Institute SC

    Tampa, Florida

  • Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2)

    Atlanta, Georgia

  • Northwest Georgia Oncology Center NW Georgia Onc

    Marietta, Georgia

  • University of Kansas Cancer Center Univ Kansas 2

    Kansas City, Kansas

  • Norton Healthcare, Inc.

    Louisville, Kentucky

  • Washington University School of Medicine Regulatory

    St Louis, Missouri

  • University of Nebraska Medical Center Unv Nebraska Med Ctr (2)

    Omaha, Nebraska

  • University of New Mexico Cancer Research Center Dept of Univ New Mexico

    Albuquerque, New Mexico

  • New York Oncology Hematology, P.C. Dept. of New York Oncology. PC

    Troy, New York

  • Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1

    Columbus, Ohio

  • University of Oklahoma Health Sciences Center OUHSC 2

    Oklahoma City, Oklahoma

  • Northwest Cancer Specialists Vancouver Loc

    Portland, Oregon

  • Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology

    Dallas, Texas

  • University of Texas Southwestern Medical Center Harry Hines

    Dallas, Texas

  • Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio

    San Antonio, Texas

  • Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA

    Reston, Virginia

  • Novartis Investigative Site

    Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Geelong, Victoria, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Charleroi, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Ottignies, Belgium

  • Novartis Investigative Site

    Sint-Niklaas, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Brno, Czech Republic, Czechia

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.